Radius Health Inc RDUS:NASDAQ

Last Price$5.84NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.05(0.85%)
Bid (Size)$5.50 (1)
Ask (Size)$6.12 (2)
Day Low / High$4.97 - 5.86
Volume2.1 M
 

View Biotechnology IndustryPeer Comparison as of 05/18/2022

 

Radius Health Inc ( NASDAQ )

Price: $5.84
Change: -0.05 (0.85%)
Volume: 2.1 M
4:00PM ET 5/18/2022
 
 

VBI Vaccines Inc ( NASDAQ )

Price: $0.97
Change: -0.10 (9.36%)
Volume: 3.2 M
4:00PM ET 5/18/2022
 
 

Precigen Inc ( NASDAQ )

Price: $1.25
Change: -0.03 (2.34%)
Volume: 961.9 K
4:00PM ET 5/18/2022
 
 

bluebird bio Inc ( NASDAQ )

Price: $3.33
Change: -0.29 (8.01%)
Volume: 2.5 M
4:00PM ET 5/18/2022
 
 

Jounce Therapeutics Inc ( NASDAQ )

Price: $4.60
Change: -0.36 (7.26%)
Volume: 329.7 K
4:00PM ET 5/18/2022
 

Read more news Recent News

-- Earnings Flash (RDUS) RADIUS HEALTH Posts Q1 Revenue $43.2M, vs. Street Est of $51.3M
7:31AM ET 5/05/2022 MT Newswires

...

-- Earnings Flash (RDUS) RADIUS HEALTH Reports Q1 Loss $-0.19, vs. Street Est of $-0.18
7:31AM ET 5/05/2022 MT Newswires

...

Radius Health Names New CFO
9:59AM ET 3/16/2022 MT Newswires

Radius Health (RDUS) said Wednesday that Mark Conley was named as its new chief financial officer Conley most recently served as vice president of finance...

Radius Files Supplemental New Drug Application With FDA for Tymlos Injection for Men With Osteoporosis
10:28AM ET 3/01/2022 MT Newswires

Radius Health (RDUS) said Tuesday it has filed a supplemental new drug application with the US Food and Drug Administration for its Tymlos injection to...

Company Profile

Business DescriptionRadius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. View company web site for more details
Address22 Boston Wharf Road
Boston, Massachusetts 02210
Phone+1.617.551.4000
Number of Employees398
Recent SEC Filing05/05/20228-K
President, Chief Executive Officer & DirectorGeorge Kelly Martin
CFO, Treasurer, Chief Accounting Officer & VPMark Conley
Chief Medical OfficerBruce Mitlak
Head-Information TechnologyAllison Ross

Company Highlights

Price Open$5.61
Previous Close$5.84
52 Week Range$4.97 - 23.00
Market Capitalization$277.8 M
Shares Outstanding47.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.54
Beta vs. S&P 500N/A
Revenue$99.2 M
Net Profit Margin-33.52%
Return on Equity29.44%

Analyst Ratings as of 01/06/2022

Buy
0
Overweight
0
Hold
5
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset